Nomura

Public sector borrowers enjoyed a storming sterling market this week and, with many of the supporting factors still in place, SSA bankers are confident that more deals will follow.

Investigators are finally baring their teeth at the bond markets, after dozens of other post-crisis scandals, with a probe into the supranational and agency market that has engulfed four banks.

The Inter-American Development Bank raised $3bn on Thursday amid a buoyant dollar market for public sector borrowers at the start of 2016.

The sterling market enjoyed a second record breaking day in a row on Wednesday as FMS Wertmanagement printed its largest ever deal in the currency — and sterling investors were impatient for an upcoming World Bank deal.

The World Bank printed a five year Kangaroo note on Wednesday to kick off the Australian dollar market for the year, which could be set for a bumper couple of months.

Westpac NZ launched a sterling senior bond on Wednesday and Santander UK will soon follow with a debut holdco deal, as FIG's first signs of life in 2016 favour the UK market.

The European Investment Bank blew the doors off the sterling market with a record breaking deal on Tuesday, and two other issuers quickly followed.

The GlobalCapital editorial team has picked what it believes to be the standout bond issues of 2015 across the corporate, high yield, public sector, financial institution and emerging market bond markets. Below are the High Yield Deals of the Year 2015.

Nomura has announced the appointment of a new non-executive chairman of Nomura Europe Holdings.

Indian hospital chain Narayana Hrudayalaya launched bookbuilding for its Rp6.13bn ($92m) IPO on Thursday, bagging the Singapore sovereign among its anchor investors.

Alkem Laboratories has priced its Rp13.5bn ($202.1m) IPO at the top end of its range, following a burst of demand for the Indian healthcare sector in the past month.

Alkem Laboratories is set to price its Rp13.5bn ($202.1m) IPO at the top of the range after investors piled into the trade, buoyed by healthy demand for the Indian pharmaceutical sector.